AMG 757 clinical trials
Also written Tarlatamab, AMG 757 and Imdelltra.
How each study uses AMG 757 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the AMG 757 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 16 May 2024 · IMDELLTRA · BLA 761344 (FDA, Drugs@FDA)
- European Union
- 29 May 2026 · Imdylltra · EMEA/H/C/006451 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
28 studies that test it; most in 2025 (11); 2 more planned to start later
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2021 | 2 |
| 2023 | 1 |
| 2024 | 4 |
| 2025 | 11 |
| 2026 | 9 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 17
Amgen (13) · Vall d'Hebron Institute of Oncology (1) · PrECOG, LLC. (1) · Maastricht University Medical Center (1) · AIO-Studien-gGmbH (1) · University of Arizona (1) · ETOP IBCSG Partners Foundation (1) · National Taiwan University Hospital (1)
Often tested with
Tested in the same studies.
Tambotatug pelitecan (1) · Temozolomide (1) · Etoposide (1) · Carboplatin (1) · Zocilurtatug Pelitecan (1) · Sacituzumab govitecan (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 6, 1 in phase 3
Studies that test AMG 757, phase 3 first.
- Sep 2027Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)Phase 3 · Amgen
- Mar 2027Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI TreatmentPhase 2 · Sehhoon Park
- Apr 2027Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)Phase 1 · Amgen
- May 2027Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)Phase 2 · Gustave Roussy, Cancer Campus, Grand Paris
- Jul 2027Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance StatusPhase 2 · AIO-Studien-gGmbH
- Aug 2027A Study of Tarlatamab for People With Prostate CancerPhase 2 · Memorial Sloan Kettering Cancer Center
Studies
Open first, then newest update. How each study uses AMG 757 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 30
- Tarlatamab Treatment Before and After Surgery in Surgically Resectable Recurrent High-grade Glioma: a Window of Opportunity Study (TARLAGLIA Study)Not yet recruitingPhase 1Vall d'Hebron Institute of OncologyNCT07788677Written as Tarlatamab
- Tarlatamab for SCLC Brain MetastasesRecruitingPhase 2Maastricht University Medical CenterNCT07402343Written as Tarlatamab
- Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance StatusRecruitingPhase 2AIO-Studien-gGmbHNCT07803848Written as Tarlatamab
- Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing TumorsRecruitingPhase 1/2University of ArizonaNCT06814496Written as Tarlatamab
- A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2RecruitingPhase 2ETOP IBCSG Partners FoundationNCT07203053Written as Tarlatamab
- Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS)RecruitingPhase 2National Taiwan University HospitalNCT06816394Written as Tarlatamab
- Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)RecruitingPhase 3AmgenNCT07778316Written as Tarlatamab
- Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System TumorsRecruitingPhase 1/2Centre Leon BerardNCT07243470Written as Tarlatamab
- Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI TreatmentRecruitingPhase 2Sehhoon ParkNCT06830694Written as Atezolizumab, Etoposide, Carboplatin, Tarlatamab
- Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)RecruitingPhase 2Gustave Roussy, Cancer Campus, Grand ParisNCT07016230Written as Tarlatamab
- A Study of Tarlatamab for People With Prostate CancerRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07111507Written as Tarlatamab
- Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)RecruitingPhase 1AmgenNCT07531095Written as Tarlatamab
- Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC PatientsRecruitingPhase 2Fundación GECPNCT07242547Written as Tarlatamab
- Tarlatamab for the Treatment of Extensive Stage Small-cell Lung CancerRecruitingPhase 2Asrar AlahmadiNCT07423585Written as Tarlatamab
- Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)RecruitingPhase 1AmgenNCT06598306Written as Tarlatamab
- Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung CancerNot yet recruitingPhase 3PrECOG, LLC.NCT07637513Written as Tarlatamab
- Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma PatientsRecruitingPhase 2Inkeun ParkNCT06893783Written as Tarlatamab
- Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)RecruitingPhase 3Intergroupe Francophone de Cancerologie ThoraciqueNCT06937905Written as Tarlatamab
- Study of How Safe and Effective Tarlatamab is in Brain CancersRecruitingPhase 2University Health Network, TorontoNCT06776250Written as Tarlatamab
- Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and DurvalumabActive, not recruitingPhase 3AmgenNCT06211036Written as Tarlatamab
See all 30 studies that test AMG 757 →
Given beside what is tested · 6 — AMG 757 is usual care or a partner of the new treatment
- A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Tarlatamab and Atezolizumab in Adult Participants With Extensive Stage-Small Cell Lung CancerNot yet recruitingPhase 2AbbVieNCT07895056Written as Tarlatamab
- A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)RecruitingPhase 1AmgenNCT07037758Written as Tarlatamab
- A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)RecruitingPhase 1GlaxoSmithKlineNCT06551142Written as Tarlatamab
- Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamabTerminatedPhase 2Grupo Espanol de Tumores NeuroendocrinosNCT07061080Written as Tarlatamab
- First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)Active, not recruitingPhase 1AmgenNCT05361395Written as Tarlatamab
- AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)CompletedPhase 1AmgenNCT04885998Written as Tarlatamab
Codes
What other systems call AMG 757 · ClinicalTrials.gg INT001867
- MeSH (NLM) C000722655AMG 757Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) 74X82ST8Q1TARLATAMABConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000722655 | AMG 757 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 74X82ST8Q1 | TARLATAMAB | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.